|1.||Cellini, Barbara: 3 articles (01/2012 - 01/2007)|
|2.||Müller, Thomas: 3 articles (06/2011 - 05/2002)|
|3.||Gordin, A: 3 articles (10/2004 - 01/2001)|
|4.||Rujescu, Dan: 2 articles (11/2014 - 04/2008)|
|5.||Giegling, Ina: 2 articles (11/2014 - 04/2008)|
|6.||Rietschel, Marcella: 2 articles (11/2014 - 07/2002)|
|7.||Paiardini, Alessandro: 2 articles (01/2012 - 12/2011)|
|8.||Bossa, Francesco: 2 articles (01/2012 - 01/2007)|
|9.||Montioli, Riccardo: 2 articles (01/2012 - 12/2011)|
|10.||Giardina, Giorgio: 2 articles (01/2012 - 12/2011)|
|1.||Parkinson Disease (Parkinson's Disease)
02/01/1996 - "We performed dynamic PET studies with fluorodopa (FDOPA) in 9 normal volunteers and 16 patients with Parkinson's disease to investigate the applicability of dopa decarboxylase (DDC) activity measurements as useful markers of the parkinsonian disease process. "
06/10/2010 - "However, neither in clinical use nor in experimental models of Parkinson's disease have the timing and dose of dopa decarboxylase inhibitors been thoroughly explored. "
11/01/2001 - "Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase."
02/01/1996 - "Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease."
09/01/1978 - "Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease."
07/01/2008 - "However, long-term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re-emergence of symptoms because of wearing-off and dyskinesia. "
07/01/2006 - "Unfortunately, chronic use of traditional levodopa/dopa decarboxylase inhibitor formulations is associated with the development of complications, such as wearing-off and dyskinesia. "
12/01/1984 - "One year ago peripheral dopa decarboxylase inhibitor in combination with L-dopa was started, and he began to have involuntary movements. "
06/10/2010 - "The novel dopa decarboxylase inhibitor, L-AMD, increased locomotor activity and improved motor disability to the same extent as carbidopa or benserazide but importantly this was accompanied by significantly less dyskinesia. "
01/01/2013 - "The aim of the study was to verify whether a combination of levodopa with DOPA decarboxylase and catechol-O-methyltransferase inhibitors (stalevo) could delay the development of dyskinesia compared to the standard two-component drug due to the more stable concentration levodopa in the blood that provided the persistent stimulation of dopamine receptors in the striatum. "
|3.||Parkinsonian Disorders (Parkinsonism)
03/01/1981 - "Levodopa with or without dopa decarboxylase is not a cure for parkinsonism. "
01/01/1985 - "Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition."
12/01/1984 - "Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism."
11/16/1979 - "[Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor]."
02/15/1975 - "[Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase]."
02/17/1978 - "There was significant antitumor activity against the neuroblastoma, which was enhanced by combination with a dopa decarboxylase inhibitor, Ro4-4602. "
01/01/1985 - "Using the neuroblastoma clone N1E-115 which lacks DOPA decarboxylase and thus contains only low levels of dopamine the site of action of certain drugs could be determined. "
07/01/1999 - "Of the 29 non-neuroblastoma tumor samples examined, the only tumor samples that expressed clearly detectable levels of both tyrosine hydroxylase and dopa decarboxylase were phaeochromocytomas. "
04/01/2010 - "Tyrosine hydroxylase and 3,4-dihydroxyphenylalanine (dopa) decarboxylase transcripts were demonstrated in 10 of 13 cases of neuroblastoma. "
12/15/2008 - "Tyrosine hydroxylase (TH), dopa decarboxylase (DDC) and GD2 synthase (GD2S) mRNAs were analyzed in 554 blood (PB) and bone marrow (BM) samples from 58 children with neuroblastoma. "
|5.||Orthostatic Hypotension (Postural Hypotension)
06/01/1990 - "Treatment of both patients with the synthetic amino acid, d-l-threo-dihydroxyphenylserine, which contains a hydroxyl group and is converted to noradrenaline by dopa-decarboxylase, reduced symptoms and signs of postural hypotension and increased levels of plasma noradrenaline and its urinary metabolites. "
03/01/1973 - "L-DOPA itself caused a pressor response in all cats.3. The dopa decarboxylase inhibitor N(1)-(DL-seryl)-N(2)-(2,3,4-trihydroxybenzyl) hydrazine (RO4-4602, 50 and 10 mg/kg) had no effect itself on the tilt response but completely prevented the effects of L-DOPA on the carotid occlusion pressor effect and postural hypotension.4. After RO4-4602 (3 and 1 mg/kg), L-DOPA (100 mg/kg) caused a brief rise of blood pressure followed by a longer lasting fall in horizontally-orientated cats (i.e. "
|1.||Levodopa (L Dopa)
|10.||Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Infusion Pumps (Infusion Pump)